You
are here:Home
/
Publications
/
Protocol for a living evidence synthesis on variants of concern and COVID-19 vaccine effectiveness
Nicole Shaver, Melanie Katz, Gideon Darko Asamoah, Lori-Ann Linkins, Wael Abdelkader, Andrew Beck, Alexandria Bennett, Sarah E Hughes, Maureen Smith, Mpho Begin, Doug Coyle, Thomas Piggott, Benjamin M. Kagina, Vivian Welch, Caroline Colijn, David J. D. Earn, Khaled El Emam, Jane Heffernan, Sheila F. O'Brien, Kumanan Wilson, Erin Collins, Tamara Navarro, Joseph Beyene, Isabelle Boutron, Dawn Bowdish, Curtis Cooper, Andrew Costa, Janet Curran, Lauren Griffith, Amy Hsu, Jeremy Grimshaw, Marc-André Langlois, Xiaoguang Li, Anne Pham-Huy, Parminder Raina, Michele Rubini, Lehana Thabane, Hui Wang, Lan Xu, Melissa Brouwers, Tanya Horsley, John Lavis, Alfonso Iorio, and Julian Little
(2023)
Protocol for a living evidence synthesis on variants of concern and COVID-19 vaccine effectiveness
Vaccine, 41(43):6411-6418.
Background It is evident that COVID-19 will remain a public health concern in the coming years, largely driven by variants of concern (VOC). It is critical to continuously monitor vaccine effectiveness as new variants emerge and new vaccines and/or boosters are developed. Systematic surveillance of the scientific evidence base is necessary to inform public health action and identify key uncertainties. Evidence syntheses may also be used to populate models to fill in research gaps and help to prepare for future public health crises. This protocol outlines the rationale and methods for a living evidence synthesis of the effectiveness of COVID-19 vaccines in reducing the morbidity and mortality associated with, and transmission of, VOC of SARS-CoV-2. Methods Living evidence syntheses of vaccine effectiveness will be carried out over one year for (1) a range of potential outcomes in the index individual associated with VOC (pathogenesis); and (2) transmission of VOC. The literature search will be conducted up to May 2023. Observational and database-linkage primary studies will be included, as well as RCTs. Information sources include electronic databases (MEDLINE; Embase; Cochrane, L*OVE; the CNKI and Wangfang platforms), pre-print servers (medRxiv, BiorXiv), and online repositories of grey literature. Title and abstract and full-text screening will be performed by two reviewers using a liberal accelerated method. Data extraction and risk of bias assessment will be completed by one reviewer with verification of the assessment by a second reviewer. Results from included studies will be pooled via random effects meta-analysis when appropriate, or otherwise summarized narratively. Discussion Evidence generated from our living evidence synthesis will be used to inform policy making, modelling, and prioritization of future research on the effectiveness of COVID-19 vaccines against VOC.
Living systematic review, COVID-19, long COVID, SARS-CoV-2 variant, Omicron, Hybrid immunity